Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP

Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)- REACT-2020

The objective of this national, prospective, multi-centre observational study is to describe the prescription rational and practice in Germany, confirm the efficacy of caplacizumab in a real-world setting, and identify predicting factors in iTTP-patients with regard to persistent autoimmune activity, therapy guidance and risk of complications. The rational is to develop new treatment algorithms that optimize overall patient outcome and reduce treatment cost.

Inclusion Criteria:

• Confirmed diagnosis of an acute episode of acquired thrombotic thrombocytopenic purpura
• Treatment with at least one single dose of caplacizumab (10 mg i.v. or s.c.)
• Male or female patients ≥ 18 years of age
• signed written informed consent

Exclusion Criteria:

• Hereditary thrombotic thrombocytopenic purpura
• disability to give informed consent